You can buy or sell Curis and other stocks, options, ETFs, and crypto commission-free!
Curis, Inc. Common Stock, also called Curis, is a biotechnology company, which is focused on the development and commercialization of drug candidates for the treatment of human cancers. Read More Its pipeline includes CUDC-907, CA-170, and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.
52 Week High
52 Week Low
What's Driving The Rally In Microcap Biotech Curis?
Thinly traded Curis, Inc. (NASDAQ: CRIS) shares weremoving notably higher Monday on roughly 35 times their average volume. What Happened Curis announced Monday ahead of the market open that it reached an agreement with funds managed by Oberland Capital Management to sell the rights to a portion of royalty revenues on worldwide net sales of Erivedge for up to $135.7 million. Curis will be paid $65 million in cash upfront, plus potential milestone payments of up to an additional $70.7 million if future net...
Biotech News: Why Curis Stock Is Soaring Today
A recent bit of biotech news involving Curis has CRIS stock flying high on Monday. Biotech News: Why Curis Stock Is Soaring Today More Source: Shutterstock Curis (NASDAQ:CRIS) has announced that it has reached a deal with Oberland Capital Management in connection to Erivedge. This has it offering selling rights for a portion of royalty revenues to the group for $135.70 million. According to Curis, the deal with Oberland Capital Management has it receiving a starting payment of $65.00 million. It is then...
Curis' stock rockets on heavy volume after $135.7 million deal to sell portion of Erivedge royalties
Shares of Curis Inc. rocketed 93% in very active premarket trade Monday, after the biotechnology company said it reached an agreement to sell a portion of royalties of its Erivedge cancer treatment for up to $135.7 million to funds managed by Oberland Capital Management LLC. Volume swelled to 1.8 million shares ahead of the open, compared with the full-day average of about 174,000 shares. Under terms of the deal, Curis received $65 million upfront, and is entitled to receive up to an additional $70.7 millio...
-$0.21 per share
Expected Mar 28, Pre-Market